Latest News in the pharma Industry

Research & Development

Regeneron announces collaboration with Mitsubishi Tanabe Pharma for investigational pain therapy fasinumab in Asia

Regeneron announces collaboration with Mitsubishi Tanabe Pharma for investigational pain therapy fasinumab in Asia

2 Oct 2015

NGF antibody fasinumab currently in Phase II/III osteoarthritis trial.

Read more 
Sanofi NDA for lixisenatide accepted for review by FDA

Sanofi NDA for lixisenatide accepted for review by FDA

30 Sep 2015

First New Drug Application for a GLP-1 receptor agonist to include CV outcomes data.

Read more 
New research to deliver cancer-killing viruses to tumour cells

New research to deliver cancer-killing viruses to tumour cells

30 Sep 2015

Oxford scientists announce laboratory success using a new linker technique to bond cell-killing agents to cancer-targeting antibodies

Read more 
Cristal Therapeutics starts clinical Phase I trial with nanomedicine CriPec docetaxel in patients with solid tumours

Cristal Therapeutics starts clinical Phase I trial with nanomedicine CriPec docetaxel in patients with solid tumours

29 Sep 2015

The CriPec platform allows for the rational design of custom-made nanomedicines for controlled release of the drug at the desired site of action resulting in an improved efficacy and tolerability.

Read more 
Syndax and Merck announce first patients dosed in phase Ib/II clinical trial of entinostat and Keytruda

Syndax and Merck announce first patients dosed in phase Ib/II clinical trial of entinostat and Keytruda

28 Sep 2015

Clinical trial to assess safety and efficacy of immuno-oncology combination in patients with advanced NSCLC or melanoma.

Read more 
Biogen and Sobi receive positive opinion from CHMP for Elocta (rFVIIIFc) for the treatment of hemophilia A

Biogen and Sobi receive positive opinion from CHMP for Elocta (rFVIIIFc) for the treatment of hemophilia A

25 Sep 2015

Elocta is a recombinant factor VIII Fc fusion protein product for the treatment of hemophilia A that, if approved, would be the first hemophilia A treatment with prolonged circulation available in the EU.

Read more 
NMI TT Pharmaservices establishes new branch in Berlin

NMI TT Pharmaservices establishes new branch in Berlin

25 Sep 2015

The new outstation will provide life science researchers with the company's proprietary DigiWest multiplex protein profiling services, to accelerate lead characterisation, disease mechanism and drug mode-of-action analyses, as well as biomarker identif...

Read more 
Charity and academic collaboration aims to find drug treatment for lymphoma

Charity and academic collaboration aims to find drug treatment for lymphoma

24 Sep 2015

MALT1 could be a promising drug target for some subsets of lymphoma, including diffuse large B cell lymphoma.

Read more 
Bausch + Lomb and Nicox announce FDA Acceptance of NDA for novel glaucoma candidate

Bausch + Lomb and Nicox announce FDA Acceptance of NDA for novel glaucoma candidate

22 Sep 2015

If approved, Vesneo will be the first nitric oxide donating prostaglandin receptor agonist available for patients with open angle glaucoma or ocular hypertension.

Read more 
Targeting DNA — protein-based sensor could detect viral infection or kill cancer cells

Targeting DNA — protein-based sensor could detect viral infection or kill cancer cells

21 Sep 2015

MIT biological engineers have developed a modular system of proteins that can detect a particular DNA sequence in a cell and then trigger a specific response, such as cell death.

Read more 
Regeneron announces agreement with BARDA for the development of new antibody treatment for Ebola

Regeneron announces agreement with BARDA for the development of new antibody treatment for Ebola

21 Sep 2015

HHS will provide initial funding of approximately $17 million to support preclinical development and antibody manufacturing. This initial funding is designed to support an Investigational New Drug application with the FDA.

Read more 
Jardiance is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

Jardiance is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

18 Sep 2015

Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company's Jardiance (empagliflozin) significantly reduced the risk of the combined endpoint of cardiovascular (CV) death, non-fatal heart attack or non-fatal stroke by 14% when added to standard of...

Read more